34 active shortage notices across 6 countries.
Last updated 1 Nov 2026 · sourced from official medicines regulators
| Country | Severity | Notices | Since | Est. resolution | Source |
|---|---|---|---|---|---|
| New Zealand | high | 4 | 16 Oct 2025 | — | Pharmac |
| Belgium | medium | 15 | 26 Nov 2025 | 19 Jul 2027 | FAMHP |
| Canada |
| medium |
| 9 |
| 1 Apr 2017 |
| 18 Dec 2026 |
| HC |
| Bosnia and Herzegovina | medium | 2 | 20 Feb 2026 | 31 Dec 2026 | ALMBIH |
| India | medium | 2 | 1 May 2026 | — | CDSCO |
| Greece | medium | 2 | 12 Dec 2025 | — | EOF |
Yes. As of the latest regulator updates, Rosuvastatin has 34 active shortage notices across 6 countries (New Zealand, Belgium, Canada, Bosnia and Herzegovina, India, Greece). Status is refreshed daily from official regulatory sources.
Regulators attribute the current Rosuvastatin shortages to manufacturing problems, product discontinuation, supply-chain disruption. The exact cause varies by country and product — each notice on this page links to the official source.
Regulator-estimated resolution dates currently range from 31 Mar 2026 to 19 Jul 2027, depending on country and product. These estimates come from the manufacturers via regulators and often change — check the per-country table above for the latest.
Every shortage notice on this page is scraped daily from an official national medicines regulator (such as the FDA, TGA, MHRA or EMA) and linked back to its source. Mederti aggregates 40+ official regulators across 35+ countries and never publishes unsourced shortage claims.
Free for individual pharmacists and clinicians — watchlists, email alerts, alternatives and country-by-country product detail.
Create a free accountData on this page is aggregated from official national medicines regulators and updated daily. It is provided for information only and requires verification before clinical use. Mederti is not affiliated with or endorsed by any regulator.